Our pharmaceutical product, pTTL – Personalised Tumour Trained Lymphocytes, provides a unique personalised cell therapy designed to very precisely target and eliminate cancer in a personalised setting, with comparably mild side effects. An open label phase Ib/IIa clinical study will be initiated in 2023.
Our tools are the proprietary technologies EpiTCer® and the software PIOR®, together capable of identifying optimal neoantigens to target and to activate and multiply T-lymphocytes with the purpose of eradicating the cancer.
Unique beads do the job
The EpiTCer® beads are designed for precise and optimal delivery and presentation of neoantigens. The size and structure of the EpiTCer® beads make them ideal targets for phagocytosis by Antigen Presenting Cells (APCs) such as macrophages or dendritic cells. The APC process the antigens coupled to the beads as a foreign object and displays the neoantigen peptides on the cell surface bound in complex with the MHC molecule. In both in vivo and in vitro settings tumor-specific T-cells from patients can expand provided that both T-cells and APC are present for cell-cell interaction.
The EpiTCer® technology is adopted in the pTTL product and can also be applied in other oncology applications such as dendritic cell vaccination and active cancer vaccination. Due to the nature of the technology, the full application area of this technology is very wide and basically covers any condition caused by a dysfunction of the immune system. Early stage collaborations projects are being evaluated with EpiTCer® beads either as a pharmaceutical product or as a tool for T-cell diagnostics for COVID-19 and in the field of multiple sclerosis.
EpiTCer® beads – efficient delivery system for patient-specific neoantigens
Neoantigens are the targets
PIOR® software is a state-of-the art tool developed by NEOGAP Therapeutics for identification, selection and ranking of tumour specific T-lymphocyte targets (neoantigen peptides) to be included in the production process for personalised T-lymphocyte therapy.
The PIOR® software platform includes machine learning to capture improvements generated within the field of neoantigen prediction and next generation sequencing. PIOR® software is efficient, highly accurate and compliant with GDPR and current industry quality standards.
Personalised neoantigens
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.